A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

NCT ID: NCT06136988

Last Updated: 2023-11-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 129 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-31
• Study Completion Date: 2028-04-30

Brief Summary

The study is a multicenter, open-label, phase Ib/II study to evaluate the efficacy and safety of docetaxel for injection (albumin-bound) (HB1801) and SG001 in combination with cisplatin and simultaneous radiotherapy versus paclitaxel in combination with cisplatin and simultaneous radiotherapy for locally advanced unresectable esophageal squamous carcinoma.

Detailed Description

This study will be conducted in two stages. The first stage (Phase Ib) is a dose-escalation study designed to determine the safety and the recommended Phase 2 dose (RP2D) of HB1801 and SG001 in combination with cisplatin and simultaneous radiotherapy for locally advanced unresectable esophageal squamous carcinoma. Patients will be assigned to receive sequentially higher doses of HB1801 once every three weeks (a Cycle) by intravenous infusion, starting at a dose of 60 mg/m^2. The second stage (Phase II) is a study to evaluate the efficacy and safety of HB1801 and SG001 in combination with cisplatin and simultaneous radiotherapy versus paclitaxel in combination with cisplatin and simultaneous radiotherapy for locally advanced unresectable esophageal squamous carcinoma. Regular visits and imaging examinations will be conducted to compare the efficacy and safety of the two groups.

Conditions

Locally Advanced Unresectable Esophageal Squamous Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HB1801 and SG001 in combination with cisplatin and simultaneous radiotherapy

SG001 360 mg, Intravenous infusion, D1, Q3W, up to approximately 2 years ; Docetaxel for Injection (Albumin-bound) (HB1801), Intravenous infusion, D1, Q3W, 60 or 75 mg/m\^2, up to 2 cycles; cisplatin for injection 25 mg/m\^2, D1-D3, Q3W, up to 2 cycles; radiotherapy (28×1.8Gy).All treatments will be administered until disease progression or intolerable toxicity.

Group Type: EXPERIMENTAL

Docetaxel for Injection (Albumin-bound)

Intervention Type: DRUG

Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W

SG001

Intervention Type: DRUG

Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W

Cisplatin for injection

Intervention Type: DRUG

Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W

Simultaneous Radiotherapy

Intervention Type: RADIATION

Radiotherapy (28×1.8Gy)

Paclitaxel in combination with cisplatin and simultaneous radiotherapy

Paclitaxel 135 mg/m\^2, Intravenous infusion, D1, Q3W; cisplatin for injection 25 mg/m\^2, D1-D3, Q3W, radiotherapy (28×1.8Gy). No other systemic antineoplastic therapy is allowed until disease progression, optimal supportive care and local palliative care are allowed.

Group Type: ACTIVE_COMPARATOR

Cisplatin for injection

Intervention Type: DRUG

Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W

Paclitaxel

Intervention Type: DRUG

Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W

Simultaneous Radiotherapy

Intervention Type: RADIATION

Radiotherapy (28×1.8Gy)

Interventions

Docetaxel for Injection (Albumin-bound)

Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W

Intervention Type: DRUG

SG001

Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W

Intervention Type: DRUG

Cisplatin for injection

Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W

Intervention Type: DRUG

Paclitaxel

Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W

Intervention Type: DRUG

Simultaneous Radiotherapy

Radiotherapy (28×1.8Gy)

Intervention Type: RADIATION

Other Intervention Names

HB1801; Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years (based on the day of signing the informed consent form).

2. Voluntarily sign the informed consent, willing and able to follow the protocol for visits, treatment and laboratory tests.

3. Locally advanced (stage II-IVa and IVb supraclavicular lymph node metastases according to AJCC 8th edition) esophageal squamous carcinoma (in the case of mixed adenosquamous carcinoma, more than 50% squamous carcinoma component can be screened) diagnosed histologically or cytologically, which is unresectable in the judgment of the principal investigator, and is amenable to definitive chemoradiotherapy (dCRT) .

4. ECOG score of 0-1 within 7 days prior to the first dose.

5. Vital organ function within 7 days prior to first dose, meeting the following criteria (no blood transfusions, no use of human granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO), and erythropoietin (EPO) within 14 days prior to the first dose):

1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

2. Platelet count (PLT) ≥ 100×10^9/L

3. Hemoglobin ≥ 80g/L

4. Serum albumin ≥ 28g/L

5. Total bilirubin ≤1.0×ULN; ALT/AST ≤1.5×ULN

6. Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min, Cockcroft-Gault formula

7. Activated Prothrombin Time (APTT) and International Normalized Ratio (INR) ≤ 1.5 x ULN.

6. Female patients of childbearing age tested negative serum pregnancy test within 7 days prior to the first dose, and patients must agree to take effective contraception from the signing of the informed consent form until 6 months after the last dose, during which time breastfeeding is not allowed; male patients must agree to take contraception and sperm donation is not allowed.

7. Have at least one evaluable lesion per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).

Exclusion Criteria

1. Active malignancy within 5 years prior to the first dose, except esophageal carcinoma studied in this trial and any locally curable tumor that has received radical therapy (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or early-stage thyroid cancer, etc).

2. History of esophageal perforation and/or esophageal fistula within 6 months prior to the first dose; or significant tumor invasion into an organ adjacent to the esophageal lesion (aorta or trachea), etc., resulting in a high risk of hemorrhage, esophageal fistula, or signs of esophageal perforation.

3. Uncontrollable plasma effusions requiring frequent drainage or medical intervention (e.g., pleural effusion, peritoneal effusion, pericardial effusion, etc.) within 7 days prior to the first dose that require additional interventions within 2 weeks of the intervention (excluding exfoliative cytology of the exudate).

4. Weight loss of 20% or more within 3 months prior to the first dose; or BMI <18.5 kg/m^2 and/or weight <30 kg.

5. Severe allergy history to albumin or docetaxel, paclitaxel, cisplatin, or monoclonal antibody drugs.

6. Patients who have received prior antitumor therapy for esophageal cancer.

7. Patients with immunodeficiency or active autoimmune disease (except a. well-controlled type I diabetes b. hypothyroidism [controlled with hormone replacement therapy] c. well-controlled celiac disease d. dermatologic that do not require systemic therapy [e.g., vitiligo, psoriasis, alopecia] e. any other condition not expected to recur in the absence of external triggers).

8. History of severe cardiovascular disease within 6 months prior to the first dose, including but not limited to:

1. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, Third-degree atrioventricular block

2. History of myocardial infarction, unstable angina, angioplasty, coronary artery bridging surgery

3. Heart failure with New York Heart Association (NYHA) classification of class III and above

4. Left ventricular ejection fraction (LVEF) <50% at screening period

5. Patients with prolonged QT/QTc interval on ECG at baseline (QTcF > 480ms, Fridericia formula: QTcF=QT/RR^0.33, RR=60/heart rate).

9. Patients with poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg during the screening period).

10. Patients with active Hepatitis B (Hepatitis B surface antigen (HBsAg) or HBcAb positive test and active stage of Hepatitis B (HBV-DNA ≥ 10^4 cps/mL or ≥ 2000 IU/mL)); Hepatitis C (Hepatitis C Antibody (Anti-HCV) positive test and a positive PCR result for HCV RNA); positive for HIV, during the screening period.

11. Patients with poorly controlled diabetes mellitus, or hypokalemia, hyponatremia, or abnormal values on corrected calcium lab tests (CTCAE 5.0 >1 grade) despite of standard drug therapy within 14 days prior to the first dose.

12. History of interstitial lung disease or non-infectious pneumonia.

13. Patients with known psychoneurologic disorders that may affect adherence to the trial, and those with a history of drug dependence;

14. Patients with severe chronic or active infections (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to the first dose. Note: Antiviral therapy for patients with viral hepatitis is permitted.

15. Have received potent inhibitors or potent inducers of CYP2C8 (for Phase Ⅱ trials only) or CYP3A4 within 14 days prior to the first dose.

16. Vaccination with a live or live attenuated vaccine (inactivated vaccines are permitted) within 28 days prior to the first dose.

17. History of major organ surgery (excluding puncture biopsy) within 28 days prior to the first dose.

18. Patients who have received antitumor therapy such as other clinical investigational drugs within 28 days prior to the first dose.

19. Patients who have received systemic glucocorticoid therapy (dose > 10 mg/day of prednisone or equivalent) within 28 days prior to the first dose.

20. Any condition that, in the opinion of the investigator, makes participation in the study inappropriate (including, but not limited to, concurrent serious or uncontrolled medical conditions, potential safety risks, interference with the interpretation of the results of the study, and adherence to the trial).

21. The patient is concurrently participating in another clinical study, unless it is an observational (non-interventional) clinical study or is in the follow-up period of an interventional study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shandong Tumor Hospital

Jinan, Shandong, China

Tianjin cancer institute &hospital

Tianjin, Tianjin Municipality, China

Countries

China

Central Contacts

Clinical Trials Information Group officer

Role: CONTACT

ctr-contact@cspc.cn

+86-0311-69085587

Facility Contacts

Jin ming Yu

Role: primary

sdyujinming@126.com

86-531-67627156

Qing song Pang

Role: primary

pangqingsong2016@163.com

86-18622221203

Other Identifiers

HB1801-008

Identifier Type: -

Identifier Source: org_study_id